Saleh Ali M. Almazam
YOU?
Author Swipe
View article: Assessing the representativeness of trials of Sodium-glucose Cotransporter- 2 inhibitors in type 2 diabetes
Assessing the representativeness of trials of Sodium-glucose Cotransporter- 2 inhibitors in type 2 diabetes Open
Background Randomised controlled trials are often criticised for excluding people with multiple long-term conditions. This study used individual participant data for 25 trials of sodium glucose co-transporter-2 inhibitors (SGLT2i) to compa…
View article: Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes Open
Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce th…
View article: Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data
Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data Open
Importance Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor analogues (GLP1ra) and dipeptidyl peptidase-4 inhibitors (DPP4i) improve hyperglycaemia and, in the case of SGLT2i and GLP1ra, reduce the risk …